AEON

AEON Biopharma Inc

May 18 • 04:00PM ET

0.8550

0.0000 0.00 %

Healthcare • Biotechnology • USA • Nano • AMEX

May 18, 10:02 AMPositive FDA biosimilar feedback and 90%+ debt reduction from May 14 update drive AEON's rebound.

Index	-	P/E	-	EPS (ttm)	-4.35	Insider Own	65.50%	Shs Outstand	25.30M	Perf Week	-3.06%
Market Cap	22.49M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	9.08M	Perf Month	-16.18%
Enterprise Value	18.87M	PEG	-	EPS next Q	-0.33	Inst Own	10.81%	Short Float	1.72%	Perf Quarter	-11.86%
Income	-60.11M	P/S	-	EPS this Y	73.42%	Inst Trans	-15.45%	Short Ratio	1.51	Perf Half Y	-9.04%
Sales	0.00M	P/B	-	EPS next Y	-	ROA	-536.00%	Short Interest	0.16M	Perf YTD	-22.27%
Book/sh	-0.66	P/C	3.60	EPS next 5Y	-	ROE	-	52W High	1.45 -41.03%	Perf Year	71.00%
Cash/sh	0.24	P/FCF	-	EPS past 3/5Y	47.46% -253.12%	ROIC	-	52W Low	0.46 85.83%	Perf 3Y	-99.89%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.98% 8.42%	Perf 5Y	-99.88%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-101.45%	Oper. Margin	-	ATR (14)	0.08	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.99	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	44.12	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.99	EPS Q/Q	-112.72%	SMA20	-8.08%	Beta	0.66	Target Price	8.40
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	-13.27%	Rel Volume	0.00	Prev Close	0.86
Employees	8	LT Debt/Eq	-	Earnings	May 14 AMC	SMA200	-10.13%	Avg Volume	103.28K	Price	0.86
IPO	Apr 12, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	34.09% -	Trades		Volume	0	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-18-23	Initiated	H.C. Wainwright	Buy	$18

May-14-26 04:05PM	AEON Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire) -9.91%
Apr-24-26 04:05PM	AEON Biopharma Sets Annual Shareholder Meeting (GlobeNewswire)
Apr-03-26 04:10PM	AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 (GlobeNewswire)
04:05PM	AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards (GlobeNewswire)
Mar-30-26 04:05PM	AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program (GlobeNewswire) -14.70%
08:00AM	Loading…
Mar-25-26 08:00AM	AEON Biopharma Announces FDA Feedback Following BPD Type 2a Meeting for the ABP-450 Biosimilar Program (GlobeNewswire)
Mar-09-26 04:05PM	AEON Biopharma Appoints John Bencich as Chief Financial Officer (GlobeNewswire) +7.48%
Mar-05-26 04:05PM	AEON Biopharma Abstract Accepted for Presentation at 2026 American Academy of Neurology (AAN) Annual Meeting (GlobeNewswire) -5.50%
Jan-21-26 04:05PM	AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions (GlobeNewswire) +13.33% -13.97%
Dec-19-25 06:00PM	AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 (GlobeNewswire) +6.93%
Dec-15-25 04:05PM	AEON Biopharma Announces Execution of Exchange Agreement with Daewoong (GlobeNewswire) +5.10% +19.21%
Nov-20-25 08:30AM	AEON Biopharma Announces First Closing of PIPE Investment and Provides Update on FDA Type 2a Meeting Scheduling (GlobeNewswire) -12.79%
Nov-14-25 08:30AM	AEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued Growth (GlobeNewswire)
Aug-12-25 04:05PM	AEON Biopharma Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) +16.08%
May-23-25 04:05PM	AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 (GlobeNewswire) +13.67%
04:05PM	Loading…
May-19-25 04:05PM	AEON Biopharma to Present at the Aegis Capital Corp. Virtual Conference 2025 (GlobeNewswire)
May-14-25 04:05PM	AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-25-25 04:05PM	AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance (GlobeNewswire) -6.43%
Apr-21-25 04:10PM	AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 (GlobeNewswire)
04:05PM	AEON Biopharma Appoints Industry Veteran Rob Bancroft as Chief Executive Officer (GlobeNewswire)
Mar-27-25 04:05PM	AEON Biopharma Announces CEO Transition (GlobeNewswire) -8.56% -7.34%
Mar-24-25 04:05PM	AEON Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire) +8.03% -7.28%
Mar-04-25 08:00AM	AEON Biopharma, Inc. to Participate in the Leerink Global Healthcare Conference (GlobeNewswire) -21.31%
Feb-24-25 02:00PM	AEON Biopharma, Inc. Announces Reverse Stock Split (GlobeNewswire) -43.89%
Feb-07-25 04:05PM	AEON Biopharma, Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards (GlobeNewswire) -6.93%
Jan-07-25 09:37AM	AEON Biopharma, Inc. Announces Closing of $20.0 Million Underwritten Public Offering (GlobeNewswire) +5.24%
Jan-06-25 09:00AM	AEON Biopharma, Inc. Announces Pricing of Approximately $20.0 Million Underwritten Public Offering (GlobeNewswire) -63.09%
Jan-03-25 08:02PM	AEON Biopharma, Inc. Announces Launch of Proposed Public Offering (GlobeNewswire)
Nov-13-24 04:05PM	AEON Biopharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -8.11% -11.35%
Sep-30-24 08:00AM	AEON Biopharma Announces Positive Outcome from FDA Biosimilar Advisory Meeting (GlobeNewswire) +13.18%
09:55AM	Loading…
Aug-21-24 09:55AM	AEON Biopharma, Inc. (AEON) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Aug-19-24 04:05PM	AEON Biopharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024 (GlobeNewswire)
Aug-12-24 04:05PM	AEON Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-09-24 08:00AM	AEON Biopharma Announces Strategic Reprioritization to Pursue a Biosimilar Pathway for ABP-450 (GlobeNewswire) +7.84%
May-29-24 09:35AM	Down -64.16% in 4 Weeks, Here's Why AEON Biopharma, Inc. (AEON) Looks Ripe for a Turnaround (Zacks) +8.70%
08:00AM	AEON Biopharma Announces Strategic Resource Reprioritization and Cost Reduction Plan (GlobeNewswire)
May-14-24 04:05PM	AEON Biopharma Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-09-24 09:35AM	AEON Biopharma, Inc. (AEON) Loses -79.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) -6.21%
08:00AM	AEON Biopharma Provides Update on Development Pipeline (GlobeNewswire)
May-03-24 04:08PM	US Equity Markets Close Higher Friday Following Weak Jobs Report (MT Newswires) -49.40%
03:55PM	Sector Update: Health Care Stocks Mixed Late Afternoon (MT Newswires)
02:37PM	Top Midday Decliners (MT Newswires)
09:05AM	Sector Update: Health Care Stocks Mixed Pre-Bell Friday (MT Newswires)
08:31AM	AEON Biopharma Shares Slump Pre-Bell After Failed Chronic Migraine Phase 2 Trial (MT Newswires)
07:00AM	AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine (GlobeNewswire)
Mar-30-24 10:53PM	CORRECTION -- AEON Biopharma Announces Redemption of Public Warrants (GlobeNewswire)
Mar-29-24 04:15PM	AEON Biopharma Announces Redemption of Public Warrants (GlobeNewswire)
03:45PM	AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Mar-19-24 04:30PM	AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine (GlobeNewswire) -11.60% -12.57%
04:29PM	AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements (GlobeNewswire)
Jan-18-24 04:05PM	AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference (GlobeNewswire) +10.35%
Dec-12-23 08:00AM	AEON Biopharma Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic Migraine (GlobeNewswire)
Nov-15-23 04:49AM	AEON Biopharma Inc Reports Q3 2023 Financial Results Amid Clinical Advancements (GuruFocus.com) +7.61%
Nov-13-23 08:15AM	AEON Biopharma Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-19-23 04:05PM	AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine (GlobeNewswire)
Aug-29-23 08:00AM	AEON Biopharma Presents Positive Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia at the International Parkinson and Movement Disorders Society Congress® (GlobeNewswire)
Aug-24-23 08:00AM	AEON Biopharma Receives Notice of Allowance from USPTO for a Patent Covering Use of Botulinum Toxins to Treat Migraine Headache (GlobeNewswire) +14.91%
Aug-16-23 07:00AM	Strathspey Crown Holdings Group, LLC Provides Clarifying Statement Regarding Form 4 Filing with SEC for Holdings in AEON Biopharma (GlobeNewswire) +7.06%
Jul-24-23 07:00AM	AEON Biopharma Announces Closing of Business Combination with Priveterra Acquisition Corp. and Provides Pipeline Update (GlobeNewswire) -15.13%

AEON Biopharma, Inc. is a biopharmaceutical company, which engages in the business of developing proprietary botulinum toxin complex, ABP-450 injection, for debilitating medical conditions. The company was founded by Robert E. Grant on February 24, 2012 and is headquartered in Irvine, CA.

PresidentMr. Robert Bancroft

Chief Legal & Strategy Officer and Corporate SecretaryMr. Alex Wilson

Chief Medical OfficerDr. Chad K. Oh M.D.

Chief Financial OfficerMr. John A. Bencich M.B.A.

Chief Accounting OfficerMs. Jennifer Sy

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
FISCHER JOST	Director	May 21 '25	Buy	0.49	60,000	29,250	266,785	May 23 04:46 PM
FISCHER JOST	Director	May 20 '25	Buy	0.51	60,000	30,360	206,785	May 21 04:50 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AEON

AEON Biopharma Inc

Upgrade your Finviz experience